Magnus Johansson

Title: Magnus Johansson: Inventor in Pharmaceutical Innovation.

Introduction

Magnus Johansson is an inventor based in Södertälje, Sweden. His patent work includes compounds investigated as GLP-1 receptor modulators, a class of compounds described for potential therapeutic use in metabolic and cardiovascular conditions. He is associated with AstraZeneca AB and is listed as an inventor on 2 patents.

Latest Patents

1. Certain 3-azabicyclo[3.1.0]hexanes as GLP-1 receptor modulators. This patent describes 3-azabicyclo[3.1.0]hexanes and their pharmaceutically acceptable salts, compositions containing them, and their potential use in therapy. The compounds are presented as GLP-1 receptor modulators that may be useful in treating or preventing cardiovascular disease and metabolic conditions, including Type 2 diabetes.

2. Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as GLP-1 receptor modulators. This patent describes compounds in these chemical families, their pharmaceutically acceptable salts, compositions containing them, and potential therapeutic uses. The disclosed compounds are presented as GLP-1 receptor modulators for possible treatment or prevention of cardiovascular disease and metabolic conditions, including Type 2 diabetes.

Career Highlights

Johansson’s listed patent contributions focus on medicinal chemistry and potential therapies involving GLP-1 receptor modulation. The patent descriptions identify possible applications in metabolic and cardiovascular health. His work is associated with AstraZeneca AB.

Collaborations

Johakim Bergman and Johan Sundell are identified as some of Johansson’s coworkers. Their names are provided in connection with his professional collaborations.

Conclusion

Magnus Johansson’s patent record highlights pharmaceutical research into GLP-1 receptor modulators and their potential applications in treating metabolic and cardiovascular conditions.